A team of researchers at the University of South Australia (UniSA) has developed a weekly injectable drug that could significantly improve the lives of people living with Parkinson’s disease. The new treatment, which offers a steady release of key medications over seven days, may eliminate the need for multiple daily pills — a major breakthrough for both patients and caregivers.Consistent Dosing, Less BurdenThe injectable has been designed to maintain consistent levels of levodopa and carbidopa — two medications that form the cornerstone of Parkinson’s treatment. These drugs typically need to be taken multiple times a day to manage symptoms effectively. However, this frequent dosing can be challenging for patients, especially older adults or those who have difficulty swallowing pills.“This new formulation is about simplifying care,” said Professor Sanjay Garg, lead researcher from UniSA’s Center for Pharmaceutical Innovation. “Our goal was to create a treatment that ensures consistent drug levels in the body, reduces dosing frequency, and makes life easier for patients.”According to the study, published in the journal Drug Delivery and Translational Research, the weekly injection uses biodegradable polymers to deliver the medications slowly and steadily into the body. The formulation can be injected under the skin or into the muscle using a fine needle — avoiding the need for surgery or implants.Promising Lab ResultsIn lab tests, the injection successfully released over 90% of levodopa and 81% of carbidopa within a seven-day period. Importantly, the biodegradable implant degraded by more than 80% during that time and showed no significant toxicity in safety evaluations.“We're not just improving how the drug is delivered — we're improving patients’ lives,” Professor Garg said. “This could be a game-changer for people with Parkinson’s who struggle with the current complex medication schedules.”The researchers also noted that this delivery platform could be adapted to treat other chronic diseases such as diabetes and cancer. Plans for clinical trials and commercial development are already underway.Understanding Parkinson’s DiseaseParkinson’s disease is a progressive neurological disorder that affects movement and coordination. It occurs when nerve cells in the brain that produce dopamine — a chemical messenger that controls movement — begin to die.Common symptoms include:Tremors or shakingMuscle stiffnessSlowed movementBalance and coordination issuesDifficulty walking or talking in advanced stagesThere is currently no cure for Parkinson’s, but medications like levodopa help manage the symptoms by replenishing dopamine levels in the brain. However, the effects of these medications can wear off quickly, requiring frequent dosing throughout the day.According to the World Health Organization, more than 8.5 million people worldwide are living with Parkinson’s disease — a number that has doubled in the past 25 years. The disease also carries a significant economic burden due to ongoing medical care, medications, and caregiving needs.A 2020 study published in The Lancet Neurology noted that the global cost of Parkinson’s could reach over $79 billion annually by 2030 if no major advancements in treatment are made.